A kinetic model for the alpha-thrombin-catalyzed conversion of plasma levels of fibrinogen to fibrin in the presence of antithrombin III.

In this study we report a kinetic model for the alpha-thrombin-catalyzed production of fibrin I and fibrin II at pH 7.4, 37 degrees C, gamma/2 0.17. The fibrin is produced by the action of human alpha-thrombin on plasma levels of human fibrinogen in the presence of the major inhibitor of alpha-thrombin in plasma, antithrombin III (AT). This model quantitatively accounts for the time dependence of alpha-thrombin-catalyzed release of fibrinopeptides A and B concurrent with the inactivation of alpha-thrombin by AT and delineates the concerted interactions of alpha-thrombin, fibrin(ogen), and AT during the production of a fibrin clot. The model also provides a method for estimating the concentration of alpha-thrombin required to produce a clot of known composition and predicts a direct relationship between the plasma concentration of fibrinogen and the amount of fibrin produced by a bolus of alpha-thrombin. The predicted relationship between the concentration of fibrinogen and the amount of fibrin produced in plasma provides a plausible explanation for the observed linkage between plasma concentrations of fibrinogen and the risk for ischemic heart disease.

• Publication year

  1991

• Venue

  Journal of Biological Chemistry

• Publication date

  1991-07-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/s0021-9258(18)98795-8PMID 2071587
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of the thrombin-fibrinogen reaction by heparin and purified cofactor.

  2009cited by this paper
• Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.

  1990cited by this paper
• The COOH-terminal domain of hirudin. An exosite-directed competitive inhibitor of the action of alpha-thrombin on fibrinogen.

  1990cited by this paper
• Heparin promotes the binding of thrombin to fibrin polymer. Quantitative characterization of a thrombin-fibrin polymer-heparin ternary complex.

  1990cited by this paper
• A new concept of fibrin formation based upon the linear growth of interlacing and branching polymers and molecular alignment into interlocked single-stranded segments.

  1990cited by this paper
• Alpha-thrombin-catalyzed hydrolysis of fibrin I. Alternative binding modes and the accessibility of the active site in fibrin I-bound alpha-thrombin.

  1990cited by this paper
• Identification and Distribution of Fibrinogen, Fibrin, and Fibrin(ogen) Products in Atherosclerosis: Use of Monoclonal Antibodies

  1989cited by this paper
• Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis.

  1989cited by this paper
• Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.

  1989cited by this paper
• Acute phase reaction, fibrinogen level and thrombus size.

  1989cited by this paper
• Clotting of bovine fibrinogen. Kinetic analysis of the release of fibrinopeptides by thrombin and of the calcium uptake upon clotting at high fibrinogen concentrations.

  1988cited by this paper
• Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity.

  1988cited by this paper
• Human fibrinogen.

  1988cited by this paper
• Inhibited thrombins. Interactions with fibrinogen and fibrin.

  1987cited by this paper
• Immunochemical characterization of fibrinogen, fibrin I, and fibrin II in human thrombi and atherosclerotic lesions.

  1987cited by this paper
• Fibrinogen and risk of cardiovascular disease. The Framingham Study.

  1987cited by this paper
• The kinetics of inhibition of alpha-thrombin in human plasma.

  1986cited by this paper
• Fibrinogen Milano II: A Congenital Dysfibrinogenaemia Associated with Juvenile Arterial and Venous Thrombosis

  1986cited by this paper
• Distribution of the thrombomodulin antigen in the rabbit vasculature.

  1986cited by this paper
• Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study.

  1986cited by this paper
• Characterization of the kinetic pathway for liberation of fibrinopeptides during assembly of fibrin.

  1985cited by this paper
• Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta

  1985cited by this paper
• Regulation of formation of factor XIIIa by its fibrin substrates.

  1985cited by this paper
• Fibrinogen and fibrin.

  1984cited by this paper
• A thrombin assay based upon the release of fibrinopeptide A from fibrinogen: definition of a new thrombin unit.

  1984cited by this paper
• Fibrinogen as a risk factor for stroke and myocardial infarction.

  1984cited by this paper
• Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to the endothelium.

  1984cited by this paper
• FIBRIN ASSEMBLY *

  1983cited by this paper
• Studies on the mechanism of thrombin. Interaction with fibrin.

  1983cited by this paper
• Thrombin activity of fibrin thrombi and soluble plasmic derivatives.

  1983cited by this paper
• Steady state kinetic parameters for the thrombin-catalyzed conversion of human fibrinogen to fibrin.

  1983cited by this paper
• Solution composition dependent variation in extinction coefficients for p-nitroaniline.

  1983cited by this paper
• Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma.

  1982cited by this paper
• Demonstration of a two-step reaction mechanism for inhibition of alpha-thrombin by antithrombin III and identification of the step affected by heparin.

  1982cited by this paper
• Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C.

  1981cited by this paper
• Fibrinogen Petoskey, a dysfibrinogenemia characterized by replacement of Arg-A alpha 16 by a histidyl residue. Evidence for thrombin-catalyzed hydrolysis at a histidyl residue.

  1981cited by this paper
• Selective immobilization of alpha-thrombin by surface-bound fibrin.

  1981cited by this paper
• Thermodynamic characterization of thrombin binding by cross-linked and non-cross-linked fibrin in the presence and absence of Ca2+.

  1980cited by this paper
• The isolation and characterization of a specific antibody population directed against the thrombin antithrombin complex.

  1980cited by this paper
• Slow, spontaneous dissociation of the antithrombin—thrombin complex produces a proteolytically modified form of the inhibitor

  1980cited by this paper
• Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization. Structural requirements, number of binding sites, and species differences.

  1980cited by this paper
• Role of endothelium in sequestration of lipoprotein and firbrinogen in aortic lesions, thrombi, and graft pseudo-intimas.

  1979cited by this paper
• The kinetics of formation and dissociation of the bovine thrombin.antithrombin III complex.

  1979cited by this paper
• The binding of thrombin by fibrin.

  1979cited by this paper
• Assembly of fibrin. A light scattering study.

  1979cited by this paper
• Affinity of fibronectin to collagens of different genetic types and to fibrinogen

  1978cited by this paper
• Synthetic peptide derivatives that bind to fibrinogen and prevent the polymerization of fibrin monomers.

  1978cited by this paper
• Chemistry of the hemostatic mechanism and its relationship to the action of heparin.

  1977cited by this paper
• The size and shape of human and bovine antithrombin III.

  1977cited by this paper
• Inactivation of human thrombin in the presence of human alpha1-proteinase inhibitor.

  1976cited by this paper
• Identification of two distinct heparin cofactors in human plasma. Separation and partial purification.

  1974cited by this paper
• The purification and mechanism of action of human antithrombin-heparin cofactor.

  1973cited by this paper
• Plasminogen: Purification from Human Plasma by Affinity Chromatography

  1970cited by this paper
• Yield stress of normal human blood as a function of endogenous fibrinogen.

  1969cited by this paper
• Physicochemical studies of bovine fibrinogen. IV. Ultraviolet absorption and its relation to the structure of the molecule.

  1968cited by this paper
• Alpha-2-macroglobulin as progressive antithrombin.

  1967cited by this paper
• Dissociation of Esterolytic and Clotting Activities of Thrombin by Trypsin-Binding Macroglobulin.∗

  1966cited by this paper
• Rheology of blood and flow in the microcirculation.

  1963cited by this paper
• The Release of Thrombin from Fibrin by Fibrinolysin

  1962cited by this paper

• Mathematical models of coagulation - Are we there yet?

  2024cites this paper
• A Review of Quantitative Systems Pharmacology Models of the Coagulation Cascade: Opportunities for Improved Usability

  2023cites this paper
• Mathematical modeling to understand the role of bivalent thrombin-fibrin binding during polymerization

  2022influential citation
• A fibrin enhanced thrombosis model for medical devices operating at low shear regimes or large surface areas

  2022cites this paper
• Computational models of hemostasis: Degrees of complexity

  2022cites this paper
• Mathematical models of fibrin polymerization: Past, present, and future

  2021cites this paper
• Factor XIII-A: An Indispensable “Factor” in Haemostasis and Wound Healing

  2021cites this paper
• Modeling Thrombin Generation in Plasma under Diffusion and Flow.

  2020cites this paper
• Computational Analysis of Acute Traumatic Coagulopathy

  2019influential citation
• Analyse de la structure du caillot en conditions physiologiques et pathologiques

  2019cites this paper
• Computational study of plasma protein adsorption and coagulation factors involved in thrombogenesis on blood contact surfaces

  2018cites this paper
• Mathematical study of thrombogenic potentiality of an implant surface

  2018cites this paper
• Correlation between the plasma fibrinogen concentration and coronary heart disease severity in Moroccan patients with type 2 diabetes. Prospective study.

  2016cites this paper
• A Mathematical Model of Venous Thrombosis Initiation.

  2016cites this paper
• Kinetic model facilitates analysis of fibrin generation and its modulation by clotting factors: implications for hemostasis-enhancing therapies.

  2014cites this paper
• How does association process affect fibrinogen hydrolysis by thrombin?

  2014cites this paper
• Full Time Course Kinetics of the Streptokinase-Plasminogen Activation Pathway*

  2013cites this paper
• A mechanistic investigation of the effect of keratin-based hemostatic agents on coagulation.

  2013cites this paper
• Nontraditional Risk Factors and Biomarkers for Cardiovascular Disease: Mechanistic, Research, and Clinical Considerations for Youth A Scientific Statement From the American Heart Association

  2011cites this paper
• Statement From the American Heart Association Mechanistic, Research, and Clinical Considerations for Youth : A Scientific Nontraditional Risk Factors and Biomarkers for Cardiovascular Disease:

  2011cites this paper
• Systems Biology of Blood Coagulation and Platelet Activation

  2011cites this paper
• Systems Biology of Coagulation Initiation: Kinetics of Thrombin Generation in Resting and Activated Human Blood

  2010cites this paper
• The Role of Different Cell Types on Thrombin Generation and Fibrin Clot Formation and Structure

  2009cites this paper
• The impact of uncertainty in a blood coagulation model.

  2009cites this paper
• Response of fractional synthesis rate (FSR) of fibrinogen, concentration of D‐dimer and fibrinolytic balance to physical activity‐based intervention in obese children

  2008cites this paper
• Thrombin generation, fibrin clot formation and hemostasis.

  2008cites this paper
• Thrombin generation and fibrin clot structure.

  2007cites this paper
• Calcium-independent phospholipase A2-catalyzed plasmalogen hydrolysis in hypoxic human coronary artery endothelial cells.

  2007cites this paper
• Novel Fluorescent Prothrombin Analogs as Probes of Staphylocoagulase-Prothrombin Interactions*

  2006cites this paper
• Determination of prothombinase activation after adding human purified prothrombin to human clot: comparison of hirudin, an activated factor II inhibitor, with DX9065a, an activated factor X inhibitor, on clot-associated thrombin and on prothrombin activation

  2005cites this paper
• Thrombin increases cardiomyocyte acute cell death after ischemia and reperfusion.

  2005cites this paper
• Influence of &ggr;′ Fibrinogen Splice Variant on Fibrin Physical Properties and Fibrinolysis Rate

  2004cites this paper
• a-Thrombin within Fibrin Clots : Inactivation of Thrombin by Antithrombin-Ill

  2003cites this paper
• Binding of Exosite Ligands to Human Thrombin

  2002cites this paper
• Role of D and E domains in the migration of vascular smooth muscle cells into fibrin gels.

  2002cites this paper
• The Amino Acid Sequence in Fibrin Responsible for High Affinity Thrombin Binding

  2001cites this paper
• Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin

  2000cites this paper
• Oil fly ash-induced elevation of plasma fibrinogen levels in rats.

  2000cites this paper
• Spatiotemporal dynamics of fibrin formation and spreading of active thrombin entering non-recalcified plasma by diffusion.

  2000cites this paper
• Hemostatic Factors and Inflammatory Disease

  1999cites this paper
• Role of Regulatory Exosite I in Binding of Thrombin to Human Factor V, Factor Va, Factor Va Subunits, and Activation Fragments*

  1999cites this paper
• Increased reactivity of platelets induced by fibrinogen independent of its binding to the IIb-IIIa surface glycoprotein: a potential contributor to cardiovascular risk.

  1999cites this paper
• Coagulation, fibrinolysis and cardiovascular disease

  1999cites this paper
• Oral Thrombin Inhibitors: Challenges and Progress

  1999cites this paper
• Contact activation of the plasma coagulation cascade. III. Biophysical aspects of thrombin-binding anticoagulants.

  1998cites this paper
• Absorption and elimination of a‐thrombin and tranexamic acid after fibrin sealant application on resected livers in rabbits

  1998cites this paper
• Selective hydrolysis of plasmalogens in endothelial cells following thrombin stimulation.

  1998cites this paper
• Thrombin activates a membrane-associated calcium-independent PLA2 in ventricular myocytes.

  1998cites this paper
• Fibrinogen deficiency is compatible with the development of atherosclerosis in mice.

  1998cites this paper
• Thrombin activates a membrane-associated calcium-independent PLA2 in ventricular myocytes.

  1998cites this paper
• Selective hydrolysis of plasmalogens in endothelial cells following thrombin stimulation.

  1998cites this paper
• Modulation of Thrombin and Heparin Activities by Fibrin

  1997cites this paper
• Inactivation of Thrombin by Antithrombin Is Accompanied by Inactivation of Regulatory Exosite I*

  1997cites this paper
• Molecular basis for the resistance of fibrin-bound thrombin to inactivation by heparin/serpin complexes.

  1997cites this paper
• Plasma Coagulation Factors

  1997cites this paper
• State-of-the-Art Review: The Preclinical and Clinical Pharmacology of Novastan (Argatroban): A Small-Molecule, Direct Thrombin Inhibitor

  1997cites this paper
• Coagulación, genética y reestenosis postangioplastia

  1997cites this paper
• Resistance of γA/γ′ Fibrin Clots to Fibrinolysis*

  1997cites this paper
• Resistance of gammaA/gamma' fibrin clots to fibrinolysis.

  1997cites this paper
• [Blood coagulation, genetics and post-angioplasty restenosis].

  1997cites this paper
• Novastan® (Brand of Argatroban): A Small-Molecule, Direct Thrombin Inhibitor

  1997cites this paper
• Release of fibrinopeptides by the slow and fast forms of thrombin.

  1996cites this paper
• Isolation and Characterization of the Fibrin Intermediate Arising from Cleavage of One Fibrinopeptide A from Fibrinogen*

  1996cites this paper
• Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB Trial)

  1996cites this paper
• Challenges in the development of orally bioavailable thrombin active site inhibitors.

  1995cites this paper
• New Approaches to the Prevention of Atherosclerosis

  1995cites this paper
• Fibrinogen in ischaemic heart disease.

  1995cites this paper
• Recent progress in the pathophysiology of fibrinogen.

  1995cites this paper
• An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey.

  1995cites this paper
• Fibrinogen and factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly. Results from The Cardiovascular Health Study.

  1995cites this paper
• Mathematical Model of Serine Protease Inhibition in the Tissue Factor Pathway to Thrombin (*)

  1995cites this paper
• Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease.

  1994cites this paper
• Regulation of Thrombin Activity by Antithrombin and Heparin

  1994cites this paper
• Haemostatic function, arterial disease and the prevention of arterial thrombosis.

  1994cites this paper
• Surface 12-lead electrocardiographic findings and plasma markers of thrombin activity and generation in patients with myocardial ischemia at rest

  1994cites this paper
• Haemostatic function and arterial disease.

  1994cites this paper
• Increased lysophosphatidylcholine content induced by thrombin receptor stimulation in adult rabbit cardiac ventricular myocytes.

  1994cites this paper
• Changes in clot deformability— a possible explanation for the epidemiological association between plasma fibrinogen concentration and myocardial infarction

  1994cites this paper
• Quantifying thrombin-catalyzed release of fibrinopeptides from fibrinogen using high-performance liquid chromatography.

  1993cites this paper
• alpha-Thrombin within fibrin clots: inactivation of thrombin by antithrombin-III.

  1993cites this paper
• The hemostatic system and coronary heart disease.

  1993cites this paper
• Mathematical analysis of a proteolytic positive-feedback loop: dependence of lag time and enzyme yields on the initial conditions and kinetic parameters.

  1993cites this paper
• The role of fibrinogen as a cardiovascular risk factor.

  1993cites this paper
• Extra-Cranial Bleeding and Other Symptoms due to Low Dose Aspirin and Low Intensity Oral Anticoagulation

  1992cites this paper
• Thrombosis and cardiovascular risk in the elderly.

  1992cites this paper
• Strenuous exercise, plasma fibrinogen, and factor VII activity.

  1992cites this paper